What if you invested in Accenture in 2001?
ACN · Technology · Data through 2026-06-01
If you invested $1,000 in Accenture in 2001
The same $1,000 in the S&P 500 would be worth $8,585(+758.5%)
The S&P 500 returned $8,585 on the same $1,000. Accenture beat the market by $3,416.
Try a different start date
Pick any month and year to see what Accenture would be worth.
Compare Accenture to another stock
See how Accenture stacks up since 2001, head to head.
What if Accenture keeps this up?
Project forward at Accenture's 10.2% historical growth rate. See 5-30 year scenarios.
Growth of $1,000
Accenture vs. S&P 500 vs. US Dollar, 2001 to present
Year-by-Year Returns
$1,000 invested in Accenture starting January 2001
| Year | Price | Value | Annual |
|---|---|---|---|
| 2001 | $10.37 | $1,000 | - |
| 2002 | $17.87 | $1,723 | +72.3% |
| 2003 | $11.47 | $1,106 | -35.8% |
| 2004 | $16.41 | $1,582 | +43% |
| 2005 | $18.06 | $1,741 | +10.1% |
| 2006 | $22.12 | $2,133 | +22.5% |
| 2007 | $26.77 | $2,582 | +21.1% |
| 2008 | $24.81 | $2,393 | -7.3% |
| 2009 | $22.98 | $2,216 | -7.4% |
| 2010 | $30.43 | $2,934 | +32.4% |
| 2011 | $38.92 | $3,754 | +27.9% |
| 2012 | $44.24 | $4,267 | +13.7% |
| 2013 | $56.72 | $5,470 | +28.2% |
| 2014 | $64.54 | $6,225 | +13.8% |
| 2015 | $69.64 | $6,717 | +7.9% |
| 2016 | $89.35 | $8,618 | +28.3% |
| 2017 | $98.36 | $9,486 | +10.1% |
| 2018 | $141.60 | $13,657 | +44% |
| 2019 | $137.74 | $13,285 | -2.7% |
| 2020 | $186.41 | $17,978 | +35.3% |
| 2021 | $223.28 | $21,534 | +19.8% |
| 2022 | $330.37 | $31,863 | +48% |
| 2023 | $264.29 | $25,490 | -20% |
| 2024 | $350.11 | $33,766 | +32.5% |
| 2025 | $376.34 | $36,296 | +7.5% |
| 2026 | $261.42 | $25,213 | -30.5% |
What this return means
$1,000 in Accenture (ACN) in 2001 grew to $12,002. That works out to +1100.2%, about 12x the original stake, as of 2026-06-01.
That is about 10.2% a year compounded, broadly in line with long-run stock market averages. The same $1,000 in an S&P 500 index fund over the same span would be about $8,585, so Accenture beat the index by roughly $3,416. The index compounded at about 8.8% a year over that period.
The path was not smooth. The best single year was 2002 at +72.3%, and the worst was 2003 at -35.8%. At its lowest point the position was down about 36% from an earlier high. These figures use split-adjusted closing prices and exclude dividends, taxes, trading fees, and inflation, so a real after-tax result would differ.
None of this is a recommendation. It is a record of what already happened, and past performance does not guarantee future results.
What if you invested $100 a month instead?
Most people do not drop a lump sum in on day one. They add a fixed amount every month. Putting $100 into Accenture at the close of every month from July 2001 through June 2026 means 300 buys and $30,000 contributed over about 25 years.
$100/month, dollar-cost averaged
$96,565
+221.9% on $30,000 in
Same $30,000, all in at the start
$360,000
+1,100.0% on $30,000 in
Going all in at the start beat spreading the buys out by $263,435. That is the usual result when a stock trends up: each monthly buy pays a higher price than the last, so the average cost climbs. Averaging in also meant an average buy price of $38.66 per share across the whole stretch, so the monthly buyer never had to time a single low. Neither number counts dividends, taxes, or trading costs.
Illustrative fixed $100/month example, not a recommendation. Figures are computed from ACN split-adjusted monthly closes through June 2026. Past performance does not guarantee future results.
Accenture at different times
See how the start year changes the outcome
More Technology investments
Compare returns across the sector
Numbers worth sharing
Occasional data drops when something interesting surfaces. No schedule, just signal.
For informational and educational purposes only. Not financial advice. Past performance does not guarantee future results. All calculations are based on split-adjusted closing prices from Yahoo Finance and do not account for dividends, taxes, or trading fees. See our methodology and full disclaimer.